Gadolinium-based nanoparticles for highly efficient T1-weighted magnetic resonance imaging
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Eun-Kyung | - |
dc.contributor.author | Kang, Byunghoon | - |
dc.contributor.author | Choi, Yuna | - |
dc.contributor.author | Jang, Eunji | - |
dc.contributor.author | Han, Seungmin | - |
dc.contributor.author | Lee, Kwangyeol | - |
dc.contributor.author | Suh, Jin-Suck | - |
dc.contributor.author | Haam, Seungjoo | - |
dc.contributor.author | Huh, Yong-Min | - |
dc.date.accessioned | 2021-09-05T07:45:59Z | - |
dc.date.available | 2021-09-05T07:45:59Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-06-20 | - |
dc.identifier.issn | 0957-4484 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98212 | - |
dc.description.abstract | We developed Pyrene-Gadolinium (Py-Gd) nanoparticles as pH-sensitive magnetic resonance imaging (MRI) contrast agents capable of showing a high-Mr signal in cancer-specific environments, such as acidic conditions. Py-Gd nanoparticles were prepared by coating Py-Gd, which is a complex of gadolinium with pyrenyl molecules, with pyrenyl polyethyleneglycol PEG using a nano-emulsion method. These particles show better longitudinal relaxation time (T1) MR signals in acidic conditions than they do in neutral conditions. Furthermore, the particles exhibit biocompatibility and MR contrast effects in both in vitro and in vivo studies. From these results, we confirm that Py-Gd nanoparticles have the potential to be applied for accurate cancer diagnosis and therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IOP PUBLISHING LTD | - |
dc.subject | MRI CONTRAST AGENTS | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | PH | - |
dc.subject | NANOCLUSTERS | - |
dc.subject | NANOCRYSTALS | - |
dc.subject | ENHANCEMENT | - |
dc.subject | NANOPROBES | - |
dc.subject | ACTIVATION | - |
dc.subject | TOXICITY | - |
dc.title | Gadolinium-based nanoparticles for highly efficient T1-weighted magnetic resonance imaging | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Kwangyeol | - |
dc.identifier.doi | 10.1088/0957-4484/25/24/245103 | - |
dc.identifier.scopusid | 2-s2.0-84901651307 | - |
dc.identifier.wosid | 000337173600003 | - |
dc.identifier.bibliographicCitation | NANOTECHNOLOGY, v.25, no.24 | - |
dc.relation.isPartOf | NANOTECHNOLOGY | - |
dc.citation.title | NANOTECHNOLOGY | - |
dc.citation.volume | 25 | - |
dc.citation.number | 24 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalResearchArea | Physics | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Physics, Applied | - |
dc.subject.keywordPlus | MRI CONTRAST AGENTS | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | PH | - |
dc.subject.keywordPlus | NANOCLUSTERS | - |
dc.subject.keywordPlus | NANOCRYSTALS | - |
dc.subject.keywordPlus | ENHANCEMENT | - |
dc.subject.keywordPlus | NANOPROBES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordAuthor | magnetic resonance image | - |
dc.subject.keywordAuthor | imaging agent | - |
dc.subject.keywordAuthor | gadolinium | - |
dc.subject.keywordAuthor | high sensitivity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.